GLP-1 Evidence

Not medical advice. A record of published research and our assessments of it. The limits

OBESIAL: A Prospective Interventional Real-world Study of a Multidisciplinary Obesity Management Programme

Status
RecruitingResults none
Why it is watched
non-weight indication: cardiovascular
Who it enrolls
age 18 Years to 65 Years; BMI ≥30 required; conditions: Obesity Difficult Airway Airway Management; Obesity Adult Onset; Obesity and Cardiovascular Risk; Obesity Type 2 Diabetes Mellitus
Interventions
Semaglutide (Wegovy) weekly injection; Behavioral Treatment; Weight loss
Conditions
Obesity Difficult Airway Airway Management; Obesity Adult Onset; Obesity and Cardiovascular Risk; Obesity Type 2 Diabetes Mellitus
Phase and size
NA · 300 participants
Dates
Start 2026-01-22
Primary completion 2028-01-23
Sponsor
University of Health Sciences, Algeria (Other)
Last checked
Sep 13, 2026
01Endpoints

What the trial will measure

  • Percentage of Participants Achieving ≥5% Weight Loss at Month 1818 months follow-up
02Eligibility

Who can take part

Inclusion Criteria: * Adults aged 18-65 years * BMI ≥30 kg/m² * Written informed consent obtained prior to enrolment Exclusion Criteria: * Refusal to participate or inability to adhere to follow-up procedures * Pregnancy at enrolment * Severe or unstable comorbidities compromising safety or participation, including: * Recent acute cardiovascular event (\<60 days) * Active malignancy * Severe unstable organic disease * Previous bariatric surgery * Obesity pharmacotherapy within the previous 90 days * Known contraindication to planned therapeutic options * Severe unstable psychiatric disorders * Genetic obesity or obesity secondary to uncontrolled endocrine disease Exclusion Criteria During Follow-up * Pregnancy occurring during follow-up * Initiation of chronic treatment associated with weight gain
03Change log

Registry changes

No changes recorded since the trial was added.